Low-risk prostate cancer patient: active treatment.
We currently lack a prospective, randomized, multicenter trial, to reassure low-risk prostate cancer patients, especially younger ones, that watchful waiting is a legitimate treatment. To better manage these patients, we need to: first, confirm that the patient has low-risk prostate cancer; second, adapt the treatment to the risk (i.e., if therapy is chosen over watchful waiting, it should be monotherapy not multiple therapy); third, be aware of age migration; fourth, know that radical prostatectomy and radiation were shown to be very effective for these patients at 10-year follow-up; and lastly, make an effort to better define watchful waiting and embrace it more, to avoid overtreatment.
Moul
Judd W
JW
Division of Urological Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Saad
Fred
F
D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000145:classification* / Q000473:pathology / Q000628:therapy*; D012306:Risk; D018570:Risk Assessment / Q000379:methods
D017430:Prostate-Specific Antigen